β‐Amyloid peptide potentiates inflammatory responses induced by lipopolysaccharide, interferon ‐γ and ‘advanced glycation endproducts’ in a murine microglia cell line
- 25 February 2003
- journal article
- research article
- Published by Wiley in European Journal of Neuroscience
- Vol. 17 (4), 813-821
- https://doi.org/10.1046/j.1460-9568.2003.02506.x
Abstract
Beta-Amyloid (Abeta) plaques are characteristic hallmarks of Alzheimer's disease (AD). In AD, it has been suggested that activation of microglial cells might be the link between Abeta deposition and neuronal degeneration. Activated microglia are associated with senile plaques and produce free radicals and inflammatory cytokines. However, it is still not clear whether Abeta needs a prestimulated environment to exert its proinflammatory potential. Advanced glycation endproducts (AGEs), protein-bound oxidation products of sugars, have been shown to accumulate in senile plaques and could induce a silent but chronic inflammation in the AD brain. We tested whether Abeta acts as an amplifier of a submaximal proinflammatory response initiated by exposure to chicken egg albumin-AGE, lipopolysaccharide or interferon-gamma. Synthetic Abeta was used to produce three different samples (Abeta-fibrilar; Abeta-aggregated; Abeta-AGE), which were characterized for beta-sheeted fibrils by the thioflavin-T test and electron microscopy. As markers of microglial activation, nitric oxide, interleukin-6, macrophage-colony stimulation factor and tumour necrosis factor-alpha production was measured. All three Abeta samples alone could not induce a detectable microglial response. The combination of Abeta preparations, however, with the coinducers provoked a strong microglial response, whereby Abeta-AGE and fibrilar Abeta were more potent inflammatory signals than aggregated Abeta. Thus, Abeta in senile plaques can amplify microglial activation by a coexisting submaximal inflammatory stimulus. Hence, anti-inflammatory therapeutics could either target the primary proinflammatory signal (e.g. by limiting AGE-formation by AGE inhibitors or cross-link breakers) or the amplifyer Abeta (e.g. by limiting Abeta production by beta- or gamma-secretase inhibitors).Keywords
This publication has 52 references indexed in Scilit:
- Amyloid-β peptide fragments p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivoJournal of Neurochemistry, 2008
- Toward the Characterization and Identification of γ-Secretases Using Transition-state Analogue InhibitorsAnnals of the New York Academy of Sciences, 2006
- α-MSH Peptides Inhibit Production of Nitric Oxide and Tumor Necrosis Factor-α by Microglial Cells Activated with β-Amyloid and Interferon γBiochemical and Biophysical Research Communications, 1999
- High molecular weight hyaluronic acid inhibits advanced glycation endproduct‐induced NF‐κB activation and cytokine expressionFEBS Letters, 1999
- Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptideJBIC Journal of Biological Inorganic Chemistry, 1998
- Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of β-amyloid peptideBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1997
- Age-dependent accumulation of advanced glycosylation end products in human neuronsNeurobiology of Aging, 1995
- Activation of Macrophages by Alzheimer β Amyloid PeptideBiochemical and Biophysical Research Communications, 1994
- Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solutionProtein Science, 1993
- The molecular pathology of Alzheimer's diseaseNeuron, 1991